
|Videos|July 9, 2020
Ground-Breaking Data from the Phase III ADAURA Trial
Author(s)Targeted Oncology
A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).



























